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Letters to the Editor 129a relatively high cumulative event rate at follow-up in multidetector
computed tomography coronary angiographic (MDCT-CA) ob-
structive coronary artery disease compared with other studies,
which may be due to characteristics of patients who had chest pain
and positive stress tests in 43% and 29% of cases, respectively.
However, the CONFIRM registry demonstrated that MDCT-CA
has the best prognostic value in this patient subset, whereas its value
in asymptomatic patients is quite limited (2). We agree that
including patients with acute coronary syndromes (ACS) may lead
to an overestimation of MDCT-CA prognostic capability. Accord-
ingly, we excluded patients in whom ACS was confirmed by cardiac
enzyme or electrocardiographic changes. The discrepancy between
hypercholesterolemia rate and statin use in our patients is in
agreement with the suboptimal therapy adherence reported in a
substantial proportion of European patients (3). Medical therapy
reported in our patients was administered before MDCT-CA.
Indeed, 26% of them were taking aspirin, not for CAD but for
other indications. We agree that the European Heart Score would
have been more appropriate than Framingham cardiovascular risk
estimation. However, the former has been challenged because it is
not mathematically consistent and unfit to estimate cardiovascular
mortality (4). In the first version of our paper, revascularizations
were defined “early” if performed within 2 months after MDCT-
CA. However, a reviewer criticized this definition. Indeed, using a
2-month cutoff, only 6 patients were excluded despite 295 patients
having MDCT-CA stenosis 70%. This indicates that many
revascularizations occurring later than 60 days were probably driven
by MDCT-CA. We agree that the 6-month cutoff may have led to
an underestimation of obstructive CAD prognostic value. However,
this limitation did not affect hard cardiac events survival analysis.
Finally, we believe that assigning 1 coronary plaque per coronary
segment and classifying a plaque as calcific in cases in which a
coronary segment contained calcific and noncalcific plaques was
correct, as previously reported (5). Indeed, in the presence of small
plaques, those calcific plaques are the easiest to detect with
MDCT-CA, and most prognostic data are based on simple
coronary plaque scores, regardless of plaque composition (3).
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Ultrasonographic Measure of
Carotid Plaque Burden
In their excellent paper, Sillesen et al. (1) omitted mention of the
original work on measurement of carotid plaque burden. Spence et
al. (2) first measured carotid total plaque area (TPA) in 1990, and
developed it for patient management and genetic research, and
3-dimensional methods for evaluation of new therapies. They
showed that TPA and progression of TPA strongly predicted the
5-year risk of stroke, death, or myocardial infarction after adjusting
for coronary risk factors.
Sillesen et al. (1) stated that the prevalence of plaque they observed
(78%) was 2-fold higher than previously reported. However, in the
NOMAS (Northern Manhattan Study) study, a population-based
study of individuals free of stroke at similar ages, plaque prevalence was
58% on 2-dimensional ultrasound imaging and it was greater by age
and among certain race-ethnic groups (3). Prevalence of plaque
epends on age and how it is defined. If defined as a focal thickening
1 mm, in vascular patients it increases from 75% of patients at age 35 to
5 years to 99% by age 65 to 75 years, and 100% over age 75 years (2).
Besides plaque burden, other ultrasonographic characteristics of
laque morphology such as plaque surface irregularity, ulceration,
exture, and plaque density may be even more important predictors
f stroke and cardiovascular disease.
The Tromsø study showed that TPA was a stronger predictor of
yocardial infarction and stroke (4) than intima-media thickness,
nd this was confirmed in a meta-analysis (5). Three-dimensional
laque volume is highly correlated with TPA, and is much more
ensitive to change with therapy than intima-media thickness or
PA, so it is the best way to assess effects of new therapies (2).
here is little doubt that carotid plaque burden will be a stronger
redictor of cardiovascular events in the High Risk Plaque Bioim-
ging Study than any of the other imaging modalities measured,
ith the possible exception of coronary calcium.
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REPLY
We appreciate the comments provided by Drs. Rundek and Spence
and recognize their important contribution to this area, docu-
mented by the cited references. We would, however, like to stress
that our data (1) were obtained in an asymptomatic population
without known cardiovascular disease, not only stroke-free as in the
Northern Manhattan Study (2), and neither “vascular patients” with
premature atherosclerosis or cerebrovascular disease as those stud-
ied by Dr. Spence (3). As previously reported (4), we agree that
ultrasonographic characteristics other than plaque size or plaque
burden may provide additional prognostic information, such as plaque
echolucency, heterogeneity, and surface irregularity and ulceration.We
also agree that the Tromsø study is important and did refer to it.
The High Risk Plaque BioImage study is the first large
population-based study with a cross-sectional evaluation of subclin-
ical arterial disease in 4 different arteries at the same baselinexamination (5), including quantitative assessment of carotid plaque
urden as described in our paper. We look forward to presenting
linical outcomes and their predictability by baseline findings in the
ear future.
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